medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2017, Number 5

<< Back Next >>

Acta Pediatr Mex 2017; 38 (5)

Neurologic crises after interruption of nitisinone in a tyrosinemia patient: case report

Ibarra-González I, Belmont-Martínez L, Cervantes-Bustamante R, Zárate-Mondragón F, Guillén-López S, Fernández-Lainez C, Revilla-Estivil N, Vela-Amieva M

Language: Spanish
References: 22
Page: 322-329
PDF size: 587.39 Kb.


ABSTRACT

We present the case of a female patient with hepatorenal tyrosinemia who presented a severe porphyria-like neurologic crisis four weeks after interrupting nitisinone treatment. The crisis was characterized by vomiting, abdominal pain, irritability, and high blood pressure, with elevation of blood succinylacetone and alpha-fetoprotein. The crisis required hospitalization and reverted totally one week after the reintroduction of nitisinone. This clinical case emphasizes the importance of maintaining nitisinone treatment uninterruptedly. This paper is useful for recognizing the clinical picture of the neurologic crises of TYR-1 and its physiopathology.


REFERENCES

  1. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY; McGraw Hill; 2001:1777-806.

  2. Raimann E, Cornejo V, Arias C, Cabello JF, Castro G, Fernández E, et al. Evolución clínica de pacientes chilenos con tirosinemia tipo I tratados con 2-(2-nitro- 4-trifluorometilbenzoil)1,3-ciclohexanediona (NTBC) Rev Med Chil. 2012;140:169-75.

  3. De Braekeleer M, Larochelle J. Genetic Epidemiology of Hereditary Tyrosinemia in Quebec and in Saguenay- Lac-St-Jean.Am J Hum Genet. 1990;47:302-307.

  4. de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1.Orphanet J Rare Dis. doi:10.1186/1750-1172-8-8.

  5. El-Karaksy H, Rashed M, El-Sayed R, El-Raziky M, El-Koofy N, El-Hawary M, et al. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr. 2010;169:689-93.

  6. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology.1994;20:1187-1191.

  7. Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz-Echevarría L. Tyrosinemia type 1 in Spain: Mutational analysis, treatment and long-term outcome. Pediatr Int. 2011;53:985-9.

  8. Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T, et al. Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1. JIMD Rep. 2015;19:43-58.

  9. Zytkovicz TH, Sahai I, Rush A, Odewale A, Johnson D, Fitzgerald E, et al. Newborn screening for hepatorenaltyrosinemia- I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program. ClinBiochem. 2013;46:681-4.

  10. Fernández-Lainez C, Ibarra-González I, Belmont- Martínez L, Monroy-Santoyo S, Guillén-López S, Vela-Amieva M. Tyrosinemia type 1: clinical and biochemical analysis of patients in Mexico. Ann Hepatol. 2014;13:265-72.

  11. Holme E, Lindstedt S. Tyrosinemia type 1 and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis. 1998;21:507-17.

  12. Gentz J, Jagenburg R, Zetterstroem R. Tyrosinemia. J Pediatr. 1965;66:670-96.

  13. Gentz J, Johansson S, Lindblad B, Lindstedt S, Zetterström R.Exertion of delta-aminolevulinic acid in hereditary tyrosinemia. ClinChimActa. 1969;23:257-63.

  14. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med. 1990;322:432-7.

  15. Lindstedt S, Holme E, Lock EA, Hjalmarrson T, Strandvik B. Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813-17.

  16. Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis. 2014;37:745-52.

  17. Acosta PB, Matalon KM. Nutrition management of patients with inherited disorders of aromatic amino acid metabolism. In Acosta PB, Nutrition Management of Patients with Inherited Metabolic Disorders. Boston, Mass; Jones and Bartlett Publishers, 2010:119-174.

  18. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis. 2000;4:805-14.

  19. Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J,et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenaltyrosinemia in Québec. Mol Genet Metab. 2012;107:49-54.

  20. Schlump JU, Perot C, Ketteler K, Schiff M, Mayatepek E, Wendel U, et. al. Severe neurological crisis in a patient with hereditary tyrosinaemia type I afterinterruption of NTBC treatment. J Inherit Metab Dis. 2008;Suppl 2:S223-5. DOI:10.1007/s10545-008-0807-z.

  21. Mungan NO, YildizdaŞ D, Kör D, Horoz ÖÖ, İncecik F, Öktem M, et. al. Tyrosinemia type 1 and irreversible neurologic crisis after one-monthdiscontinuation of nitisone. Metab Brain Dis. 2016. DOI 10.1007/s11011- 016-9833-y.

  22. Nigenda G, González-Robledo LM, Juárez-Ramírez C, Adam T. Understanding the dynamics of the Seguro Popular de Salud policy implementation in Mexico from a complex adaptive systems perspective. Implement Sci. 2016;11:68. doi:10.1186/s13012-016-0439-x.




2020     |     www.medigraphic.com